OTLK Share Price Performance

US$0.64

-0.36 (-35.61%)

US$4.90

Fair Value

US$0.64

-0.36 (-35.61%)

86.9% undervalued

US$4.90

Fair Value

US$0.64

US$4.90

US$1.60

Fri, 28 Aug 26

Fair ValueUS$4.90

Share Pricen/a

OTLK Community Narratives

AnalystConsensusTarget's

Fair Value

Fair Value US$4.9 86.9% undervalued

FDA Approval In A Massive Retina Market Will Reshape This Biologics Story

AnalystLowTarget's

Fair Value

Fair Value US$1.6 59.8% undervalued

Compounded Bevacizumab Reliance Will Pressure Retina Pricing Yet Long Term Outlook Remains Constructive

About OTLK

Founded: 2010
Employees: 17
CEO: Robert Jahr
WebsiteView website: outlooktherapeutics.com

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Recent OTLK News & Updates

Announcement • Aug 28

Outlook Therapeutics, Inc. Announces CFO Changes, Effective September 1, 2026

Outlook Therapeutics, Inc. announced the appointment of Kevin Lundquist as Chief Financial Officer, effective September 1, 2026. Mr. Lundquist brought more than 20 years of corporate finance and capital markets experience across the pharmaceutical, biotechnology, medical technology, and manufacturing industries. He had extensive experience leading finance organizations for both public and private equity-backed companies, including commercial-stage businesses, and had direct experience supporting IPOs, commercial operations, SEC reporting, investor relations, capital raising, M&A, treasury, and financial infrastructure. Mr. Lundquist most recently served as Chief Financial Officer of CapsoVision, Inc., a commercial-stage medical technology company, where he oversaw finance and operations, investor relations, SEC reporting, audit, financial planning, investment banking relationships, and capital raises. He led the company through its 2025 IPO process, and helped build its finance and accounting infrastructure, including key hires and ERP implementation. He also supported the development of the company's commercial organization and managed the P&L for approved commercial products. Previously, Mr. Lundquist served as Chief Financial Officer of Abzena Biologics, a private equity-backed contract development and manufacturing organization, where he was responsible for the company's financial and strategic direction, including IPO preparation, long-term strategy, supply chain, investor relations, banking, and board reporting. He also previously served as Vice President of Finance at Revance Therapeutics, where he oversaw financial operations, SEC reporting, treasury, capital raises, M&A, and commercial and operating strategies. Earlier in his career, Mr. Lundquist served as Global Head of Finance for Genentech/Roche's Drug Substance Biologics Operations, where he supported a global biologics manufacturing network encompassing six manufacturing sites and multiple contract manufacturers. He also served as Chief Financial Officer of Caterpillar's Japan division, overseeing a $6 billion annual-revenue business, and held a variety of finance and corporate audit positions at Abbott Laboratories. He held an M.B.A. in Finance from Utah State University and a Bachelor of Science in Accounting and Finance from the University of Utah. In connection with Mr. Lundquist's appointment, Lawrence Kenyon will step down as Chief Financial Officer effective September 1, 2026. Mr. Kenyon will continue to support the company as a non-executive employee through September 30, 2026.

Recent updates

No updates

Outlook Therapeutics, Inc. Stock Price

OTLK Share Price Performance

OTLK Community Narratives

FDA Approval In A Massive Retina Market Will Reshape This Biologics Story

Compounded Bevacizumab Reliance Will Pressure Retina Pricing Yet Long Term Outlook Remains Constructive

FDA Approval In A Massive Retina Market Will Reshape This Biologics Story

Compounded Bevacizumab Reliance Will Pressure Retina Pricing Yet Long Term Outlook Remains Constructive

Trending Discussion

Recently Updated Narratives

FDA Approval In A Massive Retina Market Will Reshape This Biologics Story

Compounded Bevacizumab Reliance Will Pressure Retina Pricing Yet Long Term Outlook Remains Constructive

Snowflake Analysis

Outlook Therapeutics, Inc. Key Details

About OTLK

Recent OTLK News & Updates

Outlook Therapeutics Names Kevin Lundquist CFO to Steer LYTENAVA Launch Transition

Outlook Therapeutics, Inc. Announces CFO Changes, Effective September 1, 2026

FDA Approval In A Massive Retina Market Will Reshape This Biologics Story

Recent updates

Outlook Therapeutics, Inc. Competitors

Ginkgo Bioworks Holdings

Editas Medicine

Rezolute

Atea Pharmaceuticals